Dr. Moez Benali, Senior Medical Director, also a member of a global team of medical monitors, holds a medical degree and board certification in oncology supported by a PhD in molecular biology and anti–cancer drug development. He has over 22 years of overall working experience, 17 of which have been within the pharmaceutical industry at regional, European and national level. As a well–rounded medical affaires strategist for over 15 years, he was able to lead activities across most life cycle management of drugs, registered and launched 11 drugs at EMA, nine of them being the standard of care. As example we can list Yervoy (ipilimumab) the historical first in class immuno–oncology drug in the melanoma field.
``Clinical development and disease management in the era of precision medecine``
